Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children

Epilepsy Research

Volumn 80, Issue 2-3, 2008, Pages 142-149

  Rauchenzauner, M ^a   Haberlandt, E ^a   Scholl Burgi S ^a   Karall, D ^a   Schoenherr, E ^a   Tatarczyk, T ^b   Engl, J ^b   Laimer, M ^b   Luef, G ^a   Ebenbichler, C F ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

sOB R leptin ratio; Soluble leptin receptor; VPA; Weight

Indexed keywords

ANTICONVULSIVE AGENT; LEPTIN; LEPTIN RECEPTOR; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CHILD; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; MONOTHERAPY; PRIORITY JOURNAL; WEIGHT CHANGE;

ADOLESCENT; ANTHROPOLOGY, PHYSICAL; ANTICONVULSANTS; BODY COMPOSITION; BODY MASS INDEX; CHILD; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; LEPTIN; MALE; RECEPTORS, LEPTIN; SEX FACTORS; VALPROIC ACID;

EID: 47549092550     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.03.017     Document Type: Article

References (48)

1. Anon. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia 30 (1989) 389-399
2. Biton V., Levisohn P., Hoyler S., Vuong A., and Hammer A.E. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J. Child Neurol. 18 (2003) 133-139
3. Biton V., Mirza W., Montouris G., Vuong A., Hammer A.E., and Barrett P.S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56 (2001) 172-177
4. Breum L., Astrup A., Gram L., Andersen T., Stokholm K.H., Christensen N.J., Werdelin L., and Madsen J. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 41 (1992) 666-670
5. Caksen H., Deda G., and Berberoglu M. Does long-term use of valproate cause weight gain in prepubertal epileptic children?. Int. J. Neurosci. 112 (2002) 1183-1189
6. Caksen H., Deda G., Berberoglu M., Icagasioglu D., and Turan E.B. Serum leptin levels in children receiving long-term carbamazepine. Acta Paediatr. Taiwan. 44 (2003) 82-83
7. Chan J.L., Bluher S., Yiannakouris N., Suchard M.A., Kratzsch J., and Mantzoros C.S. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 51 (2002) 2105-2112
8. Davis R., Peters D.H., and McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47 (1994) 332-372
9. Demir E., and Aysun S. Weight gain associated with valproate in childhood. Pediatr. Neurol. 22 (2000) 361-364
10. El-Khatib F., Rauchenzauner M., Lechleitner M., Hoppichler F., Naser A., Waldmann M., Trinka E., Unterberger I., Bauer G., and Luef G.J. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 16 3 (2007) 226-232
11. Greco R., Latini G., Chiarelli F., Iannetti P., and Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65 (2005) 1808-1809
12. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., and Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995) 543-546
13. Hall D.M., and Cole T.J. What use is the BMI?. Arch. Dis. Child 91 (2006) 283-286
14. Huang L., Wang Z., and Li C. Modulation of circulating leptin levels by its soluble receptor. J. Biol. Chem. 276 (2001) 6343-6349
15. Isojarvi J.I., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.T., and Myllyla V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. Neurol. 39 (1996) 579-584
16. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., and Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
17. Kim J.Y., and Lee H.W. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 48 (2007) 1366-1370
18. Kratzsch J., Deimel A., Galler A., Kapellen T., Klinghammer A., and Kiess W. Increased serum soluble leptin receptor levels in children and adolescents with type 1 diabetes mellitus. Eur. J. Endocrinol. 151 (2004) 475-481
19. Kratzsch J., Schubring C., Stitzel B., Bottner A., Berthold A., Thiery J., and Kiess W. Inverse changes in the serum levels of the soluble leptin receptor and leptin in neonates: relations to anthropometric data. J. Clin. Endocrinol. Metab. 90 (2005) 2212-2217
20. Kromeyer-Hauschild K., Wabitsch M., Kunze D., Geller F., Gneiß H., Hesse V., von Hippel A., Jaeger U., Johnsen D., Korte W., Menner K., Mueller G., Mueller J., Niemann-Pilatus A., Remer T., Schaefer F., Wittchen H., Zabransky S., Zellner K., Ziegler A., and Hebebrand J. Perzentilen für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr. Kinderh. 149 (2001) 807-818
21. Kuba R., Pohanka M., Zakopcan J., Novotna I., and Rektor I. Sexual dysfunctions and blood hormonal profile in men with focal epilepsy. Epilepsia 47 (2006) 2135-2140
22. Laimer M., Ebenbichler C.F., Kaser S., Sandhofer A., Weiss H., Nehoda H., Aigner F., and Patsch J.R. Weight loss increases soluble leptin receptor levels and the soluble receptor bound fraction of leptin. Obes. Res. 10 (2002) 597-601
23. Lammert A., Kiess W., Bottner A., Glasow A., and Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem. Biophys. Res. Commun. 283 (2001) 982-988
24. Landt M., Parvin C.A., and Wong M. Leptin in cerebrospinal fluid from children: correlation with plasma leptin, sexual dimorphism, and lack of protein binding. Clin. Chem. 46 (2000) 854-858
25. Leyva F., Godsland I.F., Ghatei M., Proudler A.J., Aldis S., Walton C., Bloom S., and Stevenson J.C. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 928-933
26. Luef G., Abraham I., Hoppichler F., Trinka E., Unterberger I., Bauer G., and Lechleitner M. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 51 (2002) 1274-1278
27. Luef G., Abraham I., Trinka E., Unterberger I., Hoppichler F., Bauer G., and Lechleitner M. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 57 (2001) 565-566
28. Luef G.J., Lechleitner M., Bauer G., Trinka E., and Hengster P. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res. 55 (2003) 53-58
29. Lukaski H.C., Bolonchuk W.W., Hall C.B., and Siders W.A. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J. Appl. Physiol. 60 (1986) 1327-1332
30. Maamra M., Bidlingmaier M., Postel-Vinay M.C., Wu Z., Strasburger C.J., and Ross R.J. Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology 142 (2001) 4389-4393
31. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
32. Mikkonen K., Tapanainen P., Pakarinen A.J., Paivansalo M., Isojarvi J.I., and Vainionpaa L.K. Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 45 (2004) 769-776
33. Ness-Abramof R., and Apovian C.M. Drug-induced weight gain. Drugs Today (Barc.) 41 (2005) 547-555
34. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
35. Pylvanen V., Knip M., Pakarinen A., Kotila M., Turkka J., and Isojarvi J.I. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 43 (2002) 514-517
36. Pylvanen V., Pakarinen A., Knip M., and Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 8 (2006) 643-648
37. Rattya J., Vainionpaa L., Knip M., Lanning P., and Isojarvi J.I. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 103 (1999) 588-593
38. Sandhofer A., Laimer M., Ebenbichler C.F., Kaser S., Paulweber B., and Patsch J.R. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes. Res. 11 (2003) 760-768
39. Sankar R. Initial treatment of epilepsy with antiepileptic drugs: pediatric issues. Neurology 63 (2004) S30-S39
40. Sheth R.D. Metabolic concerns associated with antiepileptic medications. Neurology 63 (2004) S24-S29
41. Stein K., Vasquez-Garibay E., Kratzsch J., Romero-Velarde E., and Jahreis G. Influence of nutritional recovery on the leptin axis in severely malnourished children. J. Clin. Endocrinol. Metab. 91 (2006) 1021-1026
42. Valle M., Gascon F., Martos R., Bermudo F., Ceballos P., and Suanes A. Relationship between high plasma leptin concentrations and metabolic syndrome in obese pre-pubertal children. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 13-18
43. Verrotti A., Basciani F., Morresi S., de Martino M., Morgese G., and Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 53 (1999) 230-232
44. Verrotti A., di Corcia G., Salladini C., Trotta D., Morgese G., and Chiarelli F. Serum insulin and leptin levels and valproate-associated obesity. Epilepsia 44 (2003) 1606
45. Verrotti A., Greco R., Latini G., and Chiarelli F. Endocrine and metabolic changes in epileptic patients receiving valproic acid. J. Pediatr. Endocrinol. Metab. 18 (2005) 423-430
46. Vorum H., Gram L., and Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res. 16 (1993) 55-64
47. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
48. Zimmet P., Boyko E.J., Collier G.R., and de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann. N.Y. Acad. Sci. 892 (1999) 25-44